Chemomab Therapeutics Ltd.
- Jurisdiction
Israel - LEI
894500LSC3H1WGG6LV25 - ISIN
US16385C1045 (CMMB )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
5
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
4
/ 7
Profile
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. Read full profile
Stock price
Fundamentals
- Net revenue
€0.00 - Gross margin
0.0% - EBIT
-€12.09M - EBIT margin
0.0% - Net income
-€11.43M - Net margin
0.0%
Statement period: - (published )
Dividends
No dividend payouts
Earnings Calls
Latest earnings call: May 14, 2023